Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00227292
Recruitment Status : Withdrawn (Mutual agreement between Sponsor and Investigator.)
First Posted : September 28, 2005
Last Update Posted : June 17, 2014
Sponsor:
Information provided by (Responsible Party):
Dr. Preuss, Martin-Luther-Universität Halle-Wittenberg

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

Chronic low back pain (CLBP) is one of the most frequent forms of chronic pain and can result in significant functional impairment. This is often associated with major depression too. Previous research reported significant beneficial effects of antidepressant medication in alleviating depression and pain intensity. The aim of this study is to evaluate the efficacy of Escitalopram, a new kind of Selective Serotonin Reuptake Inhibitor (SSRI) in patients with CLBP in a prospective, randomized and double-blind clinical trial. The main hypothesis is:

-in comparison to placebo, subjects with CLBP and Cipralex report a significant reduction in depressive symptoms (>= 50% of HAMD questionnaire) after 4 weeks of treatment.


Condition or disease Intervention/treatment Phase
Low Back Pain Depression Drug: Escitalopram Drug: Placebo Phase 4

Detailed Description:

Pain is an unpleasant sensory and emotional experience. Chronic pain, including chronic low back pain, represents a major public health problem. Risk factors of chronicity of low back pain include high levels of psychological distress prior to or during the episode, premorbid association with work status or employment dissatisfaction, unemployment, poor self-rated health and low levels of physical activity. Other psychosocial features are poor social and educational status, previous sexual or physical abuse. Furthermore, mechanical strain on the spine from heavy lifting, repetitive lifting, twisting and vibration, including driving increase the risk. Static work postures, prolonged standing or walking, road traffic accidents and falls are also significantly related.While there is little evidence for a specific personality profile, stress, distress, anxiety, mood disorders and depression were consistently related to neck and back pain.

CLBP is associated with significant disability, functional impairment, high rates of psychiatric symptoms including anxiety and depression, and loss of other physical roles. These may produce social and functional problems, which include reduced earning capacity, unemployment and family disharmony. Chronic pain is also associated with loss of self confidence and self-esteem, leading to social withdrawal and social isolation. Men with CLBP have significantly higher lifetime rates of major depression, alcohol use disorder and major anxiety disorder. After age of pain onset, CLBP subjects had over 9 times the risk of developing major depression.

Depression is believed to be mediated by 5-HT and norepinephrine through the raphe nucleus and locus coeruleus projections to the cerebral cortex and forebrain limbic systems, whereas pain is believed to be mediated in part through descending 5-HT and norepinephrine pain pathways that provide inhibitory input to the dorsal horn neurons in the spinal cord. Global deficiences in 5-HT or norepinephrine neurotransmission would be predicted to affect both mood and pain thresholds, possibly accounting for the hgh comorbidity of painful symptoms in patients with depression.Accordingly, enhancement of both neurotransmitter or 5-HT alone would be expected both to improve symptoms of depression and to normalize pain thresholds.

In antidepressant treatment of CLBP, only 2 studies were published using SSRIs. One reported significantly higher pain intensity reduction in maprotilin group compared to paroxetine and placebo. The other showed no effect of paroxetine on depression or pain. Patients on SSRI, however, reduced the amount of analgesic medication.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain
Study Start Date : November 2007
Actual Primary Completion Date : November 2012
Actual Study Completion Date : November 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Back Pain

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Placebo Comparator: A, 2, II
Placebo 10mg per day for the first week, then 20mg per day till the end of study.
 Drug: Placebo
Placebo 10mg per day for the first week, then 20mg per day till the end of study.
Experimental: A, 1
Escitalopram 10mg per day for the first week, then 20mg per day till the end of study.
 Drug: Escitalopram
Escitalopram 10mg per day for the first week, then 20mg per day till the end of study.
Other Name: Cipralex


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. In comparison to placebo-treated patients, patients with treated with Cipralex report a significant reduction in depressive symptoms (>= 50% HAMD score) after 4 weeks of treatment. [ Time Frame: 4 weeks ]

Secondary Outcome Measures :
  1. In comparison to placebo, subjects treated with Cipralex report a significant reduction in pain intensity (>= 50% reduction of pain questionnaire score or VAS) after 12 weeks of treatment. [ Time Frame: 12 weeks ]
  2. In comparison with placebo, subjects treated with Cipralex report a significant improvement in physical and everyday functioning after 12 weeks of treatment. [ Time Frame: 12 weeks ]
  3. Personality traits do not have a significant influence on outcome regarding depressive traits, pain intensity and functioning. [ Time Frame: 12 weeks ]
  4. Personality disorders are significantly influencing worse outcome regarding depressive traits, pain intensity and functioning. [ Time Frame: 12 weeks ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • In- and out-patients at KH Bethanien, Greifswald, presenting with non-specific chronic low back pain lasting longer than 6 months (assessed with VAS and OLBPQ rev.)
  • Age from 18 to 65 years
  • Depressive symptoms (HAMD scores >10)
  • Significant disability in daily living tasks (Owestry Disability Index >30%)
  • Medication with nonsteroidal anti-inflammatory drugs.

Exclusion Criteria:

  • Other significant Axis I disorders, including psychosis, eating disorders, substance use disorders or recent suicidal behavior.
  • Systemic inflammatory disorder, malignancy, other acute medical or neurological disorders, recent surgery within 12 months.
  • Medication with opioids, corticosteroids, other psychotropic medication except Temazepam.
  • History of gastric ulcer, gastritis or gastric bleeding.
  • Known allergy or intolerance to Citalopram or Cipralex.
  • Pregnant or lactating women.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00227292


Locations
Layout table for location information
Germany
Martin-Luther-University Halle
Halle, Sachsen-Anhalt, Germany, 06097
Sponsors and Collaborators
Martin-Luther-Universität Halle-Wittenberg
Investigators
Layout table for investigator information
Principal Investigator: Ulrich W Preuss, MD Krankenhaus Bethanien gGmbH
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Publications of Results:

Layout table for additonal information
Responsible Party: Dr. Preuss, Prof., Martin-Luther-Universität Halle-Wittenberg
ClinicalTrials.gov Identifier: NCT00227292    
Obsolete Identifiers: NCT00294333
Other Study ID Numbers: EudraCT Nr.2005-001673-10
JOS 05/01 ( Other Identifier: Eudra )
First Posted: September 28, 2005    Key Record Dates
Last Update Posted: June 17, 2014
Last Verified: June 2014
Keywords provided by Dr. Preuss, Martin-Luther-Universität Halle-Wittenberg:
Low back pain
Depression
Additional relevant MeSH terms:
Layout table for MeSH terms
Back Pain
Low Back Pain
Depression
Behavioral Symptoms
Pain
Neurologic Manifestations
Signs and Symptoms
Dexetimide
Citalopram
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
 Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Parasympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents